While race and ethnicity reporting in dermatology clinical trials has slightly improved in the last 5 years,1,2 the proportion of studies with adequate racial and ethnic diversity remains unchanged. Despite National Institutes of Health (NIH) diversity mandates3 and 2020 Food and Drug Administration (FDA) guidelines,4 dermatology continues to underreport race and ethnicity demographic data in clinical trials.